Cocrystal Pharma Completes Dosing in Norovirus Drug Trial, Awaits Efficacy Results
Cocrystal Pharma, Inc. has announced the completion of dosing in its Phase 1b challenge study for CDI-988, an oral antiviral drug candidate designed for norovirus prevention and treatment. The study, conducted at Emory University School of Medicine, involved 32 healthy adults aged 18 to 49. Participants were inoculated with the norovirus GII.2 strain and received either CDI-988 at 1,200 mg twice daily for five days or a placebo. No serious adverse events have been reported to date. The primary efficacy endpoint of the study is the reduction in clinical symptoms compared to placebo, with secondary endpoints including reductions in viral shedding, disease severity, safety, and pharmacokinetics. Preliminary efficacy results from this Phase 1b study are anticipated near the end of 2026. Norovirus is a highly contagious virus responsible for an estimated 21 million infections, 109,000 hospitalizations, 465,000 emergency department visits, and 900 deaths annually in the U.S., with an estimated economic burden of...